

San Francisco

Spring Group Meeting

SPECIALS

Lung Committee

Lung Committee

Leadership

Chair: Jhanelle E. Gray, MD
 Vice-Chair: Roy S. Herbst, MD, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Mary Redman, PhD
 Yingqi Zhao, PhD
 Katie Minichiello, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine:
 Biology/Pathology: Philip C. Mack, PhD
 Fred R. Hirsch, MD, PhD
 Ignacio I. Wistuba MD
 Imaging: Chadwick L. Wright MD, PhD
 Myrna C. Godoy, MD, PhD
 Radiation Oncology: Henry Park, MD
 Surgery: Wayne L. Hofstetter, MD
 Subcommittee Chairs:
 Early Stage Disease: Raymond Osarogiagbon, MD
 Eric Miguel Toloza, MD, PhD
 Locally Advanced Disease: Mary B. Daly, MD
 Tina Cascone, MD, PhD
 Shirish Gadgil, MD (Early Therapeutics)
 Metastatic Disease: Rachel E. Sanborn, MD
 Sarah B. Goldberg, MD
 Community Engagement: Paul J. Hesketh, MD
 Suzanne Cole, MD

Designates

Cancer Control Liaison: Gary E. Goodman, MD
 Veterans Affairs: Chao H. Huang, MD
 Data Coordinators: Amy Johnson, CCRP
 Kevin Moralda, BS
 Larry Kaye
 Louise Highleyman, BA
 Pasarlai Ahmadzai, MD, MPH
 Clinical Research Project Manager: TBD
 Oncology Research Professionals:
 CRA: TBD
 Nurses: Rosalie Zablocki, RN
 Lisa G. Davis, RN
 Patient Advocate: Judy Johnson, MBA
 Pharmaceutical Science: Joyce Lee, PharmD
 Safae Ghouraichi, PharmD

Protocol Project Managers: Justine Trevino
 Gabe Chadwell (Lung-MAP)
 Sr. Protocol Project Manager: Jennifer Beeler (Lung-MAP)
 Clinical Trials Program Manager: Mariah Norman, MS
 Crystal Miwa (Lung-MAP)

Time/Location

Saturday, May 3, 2025 9:30 a.m. - 12:30 p.m.

Room: Seacliff BCD (Bay Level)

Agenda

General Update & Accruals: Jhanelle E. Gray, MD

Patient Advocate Update: Judy Johnson, MBA

Thoracic Surgery Session: Eric Toloza, MD, PhD

Thoracic Radiation Session: Henry Park, MD

Translational Medicine Session: Philip C. Mack, PhD

Community Engagement Core: Paul J. Hesketh, MD

Community Engagement Champion: Lucy Gansauer, MSN, RN

Dr. Robert B. Livingston Translational Breast and Lung Cancer

Lecture: **Liquid Biopsy for Minimal Residual Disease in Lung Cancer: A Unique Opportunity for Early Intervention and Improved Outcomes** - Christian Rolfo, MD, PhD, Professor, Department of Internal Medicine at The Ohio State University College of Medicine, Associate Director for Early Phase Clinical Trials, and Director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center

Thoracic Medical Oncology: Jhanelle Gray, MD

S2414, "A randomized phase III trial incorporating pathologic response in participants with early stage non-small cell lung cancer to optimize immunotherapy in the adjuvant setting (INSIGHT)." Dr. Jeremy Cetnar

S2409, "PRISM: A Multicohort PREcision SCLC Subtype Maintenance Phase II Trial of Durvalumab Versus Biomarker-Directed Novel Agents in Combination with Durvalumab in Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Dr. Anne Chiang and Dr. Alberto Chiappori (SWOG)

CTIU2317/S2402, "Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer (PROSPECT LUNG)." Dr. Raid Aljumaily and Dr. Raymond Osarogiagbon (SWOG)

Lung Committee

S1933, "A Pilot Trial of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Activated: 6/15/20; Accrual Goal: 47; Accrual: 43. Dr. Raid Aljumaily

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Activated: 1/10/20; Accrual Goal: 668; Accrual: 269. Dr. Chad Rusthoven

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)." Activated: 1/28/19; Accrual Goal: 6000; Accrual: 3594. Dr. Karen Reckamp and Dr. David R. Gandara (SWOG)

S1900J, "A Phase II Study of Amivantamab SC in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with High MET Amplification (Lung-MAP Sub-Study)". Activated: 9/27/24; Accrual: 11. Dr. Shirish Gadgil (SWOG) and Dr. Christian Rolfo

S1900G, "A Randomized Phase II Study of Capmatinib plus Osimertinib (Tagrisso) with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-Map Sub-Study)". Activated: 4/3/23; Accrual Goal: 66 (60 eligible); Accrual: 28. Dr. Sarah Goldberg and Dr. Ross Camidge (SWOG)

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Activated: 12/18/2023; Accrual Goal: 56; Accrual: 9. Dr. Paul Paik (ECOG-ACRIN) and Xiuning Le (SWOG)

Open Discussion

Active Studies

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)." Drs. Borghaei, Reckamp, Gandara, et al. Activation: 1/28/19.

S1900G, "A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge. Activation: 4/3/23.

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Paik and Le. Activation: 12/18/23.

S1900J, "A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Rolfo and Gadgil. Activation: 9/27/24.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20.

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20.

S1933, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20.

CTSU/A081801, "Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)." Dr. Gray. Activation: 6/3/20.

CTSU/A151216, "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)." Dr. Gandara. Activation: 8/18/14.

CTSU/EA5182, "Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)." Dr. Goldberg. Activated: 10/22/20.

CTSU/NRG-LU007, "Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial." Dr. Park. Activated: 8/17/20.

Closed Studies

CTSU/NRG-CC003, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

S1800A, "A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent

Lung Committee

Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)."

Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

S1800D, "A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)." Drs. Wrangle and Husain. Activation: 2/15/22. Permanently closed: 3/10/23.

S1900A, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.

S1900B, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.

S1900C, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Padua and Gerber. Activation: 4/2/21. Permanently closed: 12/27/24.

S1900F, "A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)." Drs. Gray and Elamin. Activation: 7/25/22. Permanently closed: 6/27/23.

S1929, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22; Step 2 Permanently Closed 10/15/22.

S1934, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small

Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22; Permanently closed 3/1/23.

CTSU/EA5163/S1709, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19. ; Closed to accrual: 3/1/24.

S1701, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18; Closed to accrual: 10/15/22.

S2302, "PRAGMATICA: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer" Drs. Reckamp and Dragnev. Activation: 3/6/23; Closed to accrual: 12/20/24.

CTSU/E4512, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14; Closed to accrual: 5/10/24.

CTSU/EA5181, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activation: 4/9/20; Closed to accrual: 11/20/23.

CTSU/NRG-LU002, "Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21; Closed to accrual: 12/06/23.

CTSU/NRG-LU005, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab." Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22; Closed to accrual: 12/31/23.

CTSU/EA5191, "A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC." Dr. Massarelli. Activated: 5/22/20; Closed to accrual: 10/13/23.

Lung Committee

NCI-Approved Concepts

S1800E, “A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study).” Drs. Waqar and Li.

S2404, “Accelerating Drug Efficacy Evaluation thru Growth Rate and Overall Survival Correlations” Dr. Lawrence Schwartz and Dr. Karen Reckamp.

Concepts in Development

S1800G, “A Randomized Phase II Study of Casdozokitug with or without Toripalimab in Participants with Previously Treated Relapsed or Refractory Advanced Lung Squamous Cell Carcinoma (NRG Lung-MAP Non-match Sub-Study).” Drs. Henick and Marron.

S1900N, “A Randomized Phase II Study of Sacituzumab Govitecan alone, Ivonescimab alone, or Sacituzumab Govitecan and Ivonescimab in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).” Drs. Scott and Riess.

S2409, “PRISM: PREcision in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)” Drs. Chiang, Chiappori, Kim, et al.

S2414, “Incorporating Pathologic Response in Patients with Early Stage Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT).” Drs. Cetnar and Osarogiabon.

Publications

The publications listed below were received by the Group Chair’s Office as published (including online), accepted, or submitted since the SWOG Fall 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

S1701 S1701 A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma. Tsao A, Hsieh M, Koczywas M, Tu J, Riess J, Tanvetyanon T, Ma B, Zhao Y, Redman M, Edelman M, Gandara D, Gray

J, Kelly K. JTO Clin Res Rep Oct 16;5(12):100738, 2024.

<https://pubmed.ncbi.nlm.nih.gov/39619274/>

S1929 Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929. Abdel Karim N, Miao J, Reckamp K, Gay C, Byers L, Zhao Y, Redman M, Carrizosa D, Wang W, Petty W, Mehta K, Faller B, Agamah E, Kasbari S, Malisetti R, Kumar A, Schallenkamp J, Alluri K, Gray J, Kelly K. J Thorac Oncol Mar;20(3):383-394, 2025. <https://pubmed.ncbi.nlm.nih.gov/39505259/>

S1400 Lung-MAP Next Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400). Kozono D, Hua X, Wu M, Tolba K, Waqar S, Dragnev K, Cheng H, Hirsch FR, Mack P, Gray JE, Kelly K, Borghaei H, Herbst RS, Gandara DR, Redman M. J Thorac Oncol Dec;19(12):1618-1629, 2024. <https://pubmed.ncbi.nlm.nih.gov/3911731/>

Submitted Manuscripts

S0819 External validation of a novel computed tomography-based prognostic radiomic signature in patients with metastatic non-small cell lung cancer:correlative analysis of SWOG S0819 phase III randomized trial. Dercle L, Gomez D, Zhao B, Hama J, Kelly K, Redman M, Gandara D, Schwartz L, Gray JE. Submitted.

Lung Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	LUNGMAP	S1827	S1900E	S1900G	S1900J	S1900K	S1914	S1933	S2302	A081801
Ascension Via Christi Hospitals Wichita	1	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	1	-	-	-	-	1	-	-	1
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	2	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	36	3	2	-	-	-	10	1	16	4
Baylor College of Medicine/Duncan Comprehensive Cancer Cntr	-	5	-	-	-	-	-	-	-	-
Boston Medical Center	-	6	-	-	-	-	-	-	2	-
CWRU Case Comprehensive Cancer Center LAPS	11	2	2	-	-	-	-	-	18	15
Cancer Research Consortium of West Michigan NCORP	3	-	-	-	-	-	7	-	3	-
Cancer Research for the Ozarks NCORP	44	-	-	-	-	-	9	4	5	-
Cancer Research of Wisconsin & Northern Michigan Consortium	34	5	4	-	-	-	8	-	8	-
Carle Cancer Center NCI Comm Oncology Research Program	3	1	1	-	-	-	6	-	8	-
Cedars-Sinai Medical Center	21	-	1	1	-	-	4	-	9	-
City of Hope Comprehensive Cancer Center	5	1	-	-	-	-	-	-	3	-
Columbia University Minority Underserved NCORP	13	-	-	-	-	-	-	1	7	-
Columbus NCI Comm Oncology Research Program	28	5	-	-	-	-	-	-	4	-
CommonSpirit Health Research Institute	39	1	-	-	-	-	1	-	1	-
Corewell Health William Beaumont University Hospital	-	-	-	-	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	2	-	-	-	-	-	-	-	-	1
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	-	-	2	-
Essentia Health NCI Comm Oncology Research Program	16	-	-	-	-	-	3	-	-	-
Fred Hutchinson Cancer Research Center LAPS	4	-	-	-	-	-	-	-	10	-
Froedtert & the Medical College of Wisconsin LAPS	2	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	6	1	-	-	-	-	2	1	-	-
Georgia NCI Comm Oncology Research Program	65	3	1	-	-	-	9	-	18	-
Grupo Oncologico Cooperativo de Investigacion	-	1	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	24	1	-	-	-	-	3	-	7	1
Hartford Hospital	1	-	-	-	-	-	-	-	4	-
Hawaii Minority Underserved NCORP	27	2	-	-	-	-	-	-	7	-
Heartland Cancer Research NCORP	149	9	6	-	-	-	40	5	52	-
Henry Ford Health Providence Southfield Hospital	13	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	7	-	-	-	-	-	-	-	-	2
Houston Methodist Hospital	-	-	-	-	-	-	-	-	2	-
Instituto Nacional De Cancerologia de Mexico	-	5	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	90	-	8	-	-	-	3	-	27	5
Kansas City Veterans Affairs Medical Center	3	-	-	-	-	-	-	-	1	-
Lahey Hospital & Medical Center	32	-	-	-	-	-	4	2	12	-
Loma Linda University Medical Center	6	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	25	-	-	-	-	-	1	-	8	-
Malcom Randall Veterans Administration Medical Center	18	-	-	-	-	-	-	-	4	-
Massachusetts Vets Epidemiology Research & Information Cntr	65	4	1	-	-	-	-	-	9	12
Medical U of South Carolina Minority Underserved NCORP	22	-	2	1	-	-	-	-	19	-
Mercy Medical Center - Des Moines	8	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	111	2	7	2	-	-	12	-	18	-
Mission Hospital	1	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	18	1	1	1	-	-	-	-	52	25

Lung Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	LUNGMAP	S1827	S1900E	S1900G	S1900J	S1900K	S1914	S1933	S2302	A081801
Montana Cancer Consortium NCORP	25	-	1	-	-	-	1	1	1	-
Mount Sinai Hospital	-	-	-	-	-	-	9	-	2	-
MultiCare Tacoma General Hospital	-	-	-	-	-	-	-	-	3	-
NCORP of the Carolinas	20	-	1	-	-	-	-	-	-	-
National Cancer Center-Korea	-	1	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	14	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	99	1	2	-	-	-	8	1	3	-
Northwell Health NCORP	-	-	-	-	-	-	1	-	-	1
Northwestern University LAPS	27	1	-	1	-	-	-	-	18	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	6	-
Oregon Health & Science University	11	-	-	1	-	-	1	-	3	8
Pacific Cancer Research Consortium NCORP	21	-	-	-	-	-	-	-	1	-
Saint Joseph Hospital - Cancer Centers of Colorado	1	-	-	-	-	-	1	-	-	1
Salem Hospital	7	-	2	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	52	7	1	-	-	-	14	-	7	-
Sutter Cancer Research Consortium	48	-	1	-	-	-	-	-	1	-
The Don & Sybil Harrington Cancer Center	13	-	1	-	-	-	-	-	-	-
The James Graham Brown Cancer Center at U of Louisville	-	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	40	1	2	1	-	-	11	-	15	1
UC Irvine Health/Chao Family Comprehensive Cancer Center	30	1	-	-	-	-	5	-	1	-
UC San Diego Moores Cancer Center	16	-	1	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	74	11	7	-	-	-	2	4	10	-
USC Norris Comprehensive Cancer Center LAPS	-	5	-	-	-	-	7	-	3	-
U of Alabama at Birmingham / Deep S Research Consortium LAPS	-	-	-	-	-	-	-	-	12	-
University of Arkansas for Medical Sciences	11	-	-	-	-	-	17	-	12	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	14	4	-	1	-	-	6	-	3	2
University of Kansas Cancer Center - MCA Rural MU NCORP	98	1	1	-	-	-	-	-	5	1
University of Kentucky/Markey Cancer Center	53	1	-	-	-	-	-	-	9	-
University of Michigan Comprehensive Cancer Center LAPS	1	-	-	-	-	-	-	-	6	-
University of Mississippi Medical Center	1	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	33	1	-	-	-	-	6	15	10	-
University of Rochester LAPS	67	-	6	-	-	-	3	-	14	-
University of Texas Health Science Center at San Antonio	-	2	-	-	-	-	-	-	22	-
University of Texas MD Anderson Cancer Center LAPS	3	6	-	-	-	-	6	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	4	-	-	-	-	5	-	4	-
Upstate Carolina NCORP	41	3	-	-	-	-	3	-	1	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	10	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	2	-	-	-	-	-	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	41	1	1	-	-	-	13	-	5	-
Yale University - Yale Cancer Center LAPS	26	5	3	2	-	-	11	-	14	7
ALLIANCE	858	22	21	3	1	1	42	5	154	-
CCTG	-	33	-	-	-	-	-	-	-	-
ECOG-ACRIN	363	10	19	-	-	2	31	-	90	-
NRG	479	71	12	3	-	-	91	1	55	-
Total	3,543	251	118	17	1	3	417	41	838	87

Lung Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	A082002	A151216	E4512	EA5162	EA5163	EA5181	EA5182	EA5191	EA5221	NRGLU002
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	1	-	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	-	7	2	-	-	10	-	-	-	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	-	26	-	-	1	1	2	-	-	1
Baylor College of Medicine/Duncan Comprehensive Cancer Cntr	-	-	-	-	-	-	-	-	-	-
Boston Medical Center	-	3	-	-	-	2	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	59	-	-	17	21	1	4	-	-
Cancer Research Consortium of West Michigan NCORP	-	1	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	5	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	1	-	-	-	-
Columbus NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	2	-	-	-	-	-	-	-	-
Corewell Health William Beaumont University Hospital	-	2	-	-	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	3	-	-	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	8	-	-	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	-
Essentia Health NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	15	-	-	-	4	-	-	-	-
Froedtert & the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
Georgia NCI Comm Oncology Research Program	-	10	-	-	1	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	1	-	-	3	-	-	-	-	-
Hartford Hospital	-	-	-	-	-	-	1	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	1	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	15	2	1	2	3	-	1	-	-
Henry Ford Hospital	-	29	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	8	-	-	1	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	206	6	-	8	-	6	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	-	-	-	-	-	-	1	-
Lahey Hospital & Medical Center	-	30	-	-	2	-	-	-	-	-
Loma Linda University Medical Center	-	10	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	26	-	-	2	2	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-	-	-	-	-	-	-
Massachusetts Vets Epidemiology Research & Information Cntr	-	34	-	-	3	-	-	2	-	-
Medical U of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Mission Hospital	-	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	83	1	-	5	-	-	-	-	-

Lung Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	A082002	A151216	EA512	EA5162	EA5163	EA5181	EA5182	EA5191	EA5221	NRGLU002
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	1	8	-	-	-
MultiCare Tacoma General Hospital	-	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas	-	1	-	-	-	-	-	-	-	-
National Cancer Center-Korea	-	-	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Oregon Health & Science University	-	24	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	4	-	-	-	-	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	3	-	-	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	1	11	-	-	-	3	-	-	-	-
The Don & Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	-	-
The James Graham Brown Cancer Center at U of Louisville	-	5	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	2	46	1	-	6	-	1	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	15	1	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	5	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	12	-	-	-	-	-	-	-	-
U of Alabama at Birmingham / Deep S Research Consortium LAPS	-	-	-	-	-	-	-	-	-	-
U of Arkansas for Medical Sciences	-	3	1	-	1	3	-	-	-	-
U of Cincinnati Cancer Center-UC Medical Center	-	24	1	-	2	-	1	-	-	-
U of Colorado Cancer Center LAPS	-	58	2	-	-	-	-	1	-	-
U of Kansas Cancer Center - MCA Rural MU NCORP	-	31	-	-	7	-	-	3	-	-
U of Kentucky/Markey Cancer Center	1	5	-	-	-	-	-	-	-	-
U of Michigan Comprehensive Cancer Center LAPS	-	62	-	-	-	-	-	-	-	-
U of Mississippi Medical Center	-	26	-	-	-	-	-	-	-	-
U of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	1	-	-	-	-
U of Rochester LAPS	-	-	-	-	6	19	-	-	-	-
U of Texas Health Science Center at San Antonio	-	-	-	-	2	-	-	-	-	-
U of Texas MD Anderson Cancer Center LAPS	-	2	1	-	-	-	-	-	-	-
U of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	1	-	-	-	-	-
Upstate Carolina NCORP	-	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	1	-	-	-	-	-	-	-	1
Western States Cancer Research NCORP	-	1	-	-	-	-	1	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	57	4	-	14	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-
Total	4	984	22	1	84	72	21	11	1	2

Lung Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGLU005	NRGLU006	NRGLU008	R1308
Ascension Via Christi Hospitals Wichita	-	-	-	-
Banner MD Anderson Cancer Center	2	-	-	-
Banner U Medical Center - Tucson	1	-	-	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	4	-	1	-
Baylor College of Medicine/Duncan Comprehensive Cancer Cntr	-	3	-	-
Boston Medical Center	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-
Columbia U Minority Underserved NCORP	-	-	-	-
Columbus NCI Comm Oncology Research Program	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	-	-	-
Duke U - Duke Cancer Institute LAPS	-	-	-	-
Essentia Health NCI Comm Oncology Research Program	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-
Froedtert & the Medical College of Wisconsin LAPS	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-
Georgia NCI Comm Oncology Research Program	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-
Hartford Hospital	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-
Henry Ford Hospital	-	-	-	-
Houston Methodist Hospital	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	-	-
Lahey Hospital & Medical Center	-	-	-	-
Loma Linda U Medical Center	-	-	-	1
Loyola U Medical Center	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-
Massachusetts Vets Epidemiology Research & Information Cntr	-	-	-	-
Medical U of South Carolina Minority Underserved NCORP	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-
Mission Hospital	-	-	-	-
Moffitt Cancer Center	-	-	-	-

Lung Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGLU005	NRGLU006	NRGLU008	R1308
Montana Cancer Consortium NCORP	-	-	-	-
Mount Sinai Hospital	1	-	-	-
MultiCare Tacoma General Hospital	-	-	-	-
NCORP of the Carolinas	-	-	-	-
National Cancer Center-Korea	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-
Northwell Health NCORP	-	-	-	-
Northwestern University LAPS	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-
Oregon Health & Science University	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	-
Salem Hospital	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-
Sutter Cancer Research Consortium	-	-	1	-
The Don & Sybil Harrington Cancer Center	-	-	-	-
The James Graham Brown Cancer Center at University of Louisville	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-
U of Alabama at Birmingham / Deep S Research Consortium LAPS	-	-	-	-
U of Arkansas for Medical Sciences	1	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-
University of Colorado Cancer Center LAPS	1	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	2	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-
University of Mississippi Medical Center	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-
University of Rochester LAPS	1	-	-	-
University of Texas Health Science Center at San Antonio	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Program	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-
ALLIANCE	-	-	-	-
CCTG	-	-	-	-
ECOG-ACRIN	-	-	-	-
NRG	-	-	-	-
Total	13	3	2	1

